Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S., U.K. and European osteosarcoma key ...

Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the ...

Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

OS Therapies Incorporated OSTX shares are up during Tuesday’s premarket session as the company is providing a global ...

Osteosarcoma is a type of bone cancer. It can develop at any age, but most cases occur during childhood, early adolescence, and young adulthood. In young people, osteosarcoma tends to develop in the ...

Osteosarcoma and Ewing sarcoma are bone cancers that primarily affect children, teens, and young adults. Symptoms they share include bone pain, stiffness, and swelling at the tumor site. About 2% of ...

Osteosarcoma is the earliest identified hominin cancer. It was found in a 1.7-million-year-old hominin fossil in South Africa and has also been identified in a 77-million-year-old dinosaur specimen. 1 ...

OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer ...